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Abstract:  Cells  communicate  with  each  other  and  the  outside  world  through  surface 
receptors, which need to be tightly regulated to prevent both overstimulation and receptor 
desensitization. Understanding the processes involved in the homeostatic control of cell 
surface receptors is essential, but we are not alone in trying to regulate these receptors. 
Viruses, as the ultimate host pathogens, have co-evolved over millions of years and have 
both pirated and adapted host genes to enable viral pathogenesis. K3 and K5 (also known 
as  MIR1 and  MIR2) are  viral ubiquitin E3 ligases  from Kaposi’s Sarcoma Associated 
Herpesvirus (KSHV) which decrease expression of a number of cell surface receptors and 
have  been  used  to  interrogate  cellular  processes  and  improve  our  understanding  of 
ubiquitin-mediated receptor endocytosis and degradation. In this review, we summarize 
what has been learned from the study of these viral genes and emphasize their role in 
elucidating the complexity of ubiquitin in receptor regulation. 
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1. Introduction 
Our understanding of the importance of ubiquitin in the regulation of different cellular processes 
has increased dramatically over the past twenty-five years [1–3]. One pathway controlled by ubiquitin 
is  the  regulation  of  cell  surface  receptors  and  their  downstream  signaling  partners.  Indeed  the 
complexity of the ubiquitin system allows a fine-tuning of this pathway. Ubiquitin is an evolutionarily 
conserved  76  amino  acid  protein  that  modifies  protein  substrates  through  the  cascade  activity  of 
effector proteins. It is activated through the ATP-dependent activity of the cellular E1 protein. The 
activated ubiquitin is transferred to one of 37 cellular E2 or ubiquitin conjugating enzymes and then 
directed to its cellular target through the activity of the E3 ligase—predicted to number up to 600 per 
cell [4,5]. The complexity of the ubiquitin system comes from a combinatorial increase in the number 
of modifications. Post-translational modification by ubiquitin can occur at a single site (monoubiquitination) 
or at multiple sites (multiple monoubiquitination), and from the first ubiquitin modification, a chain of 
ubiquitin molecules can be generated (polyubiquitination) through the formation of an isopeptide bond 
between the C-terminal glycine of the incoming ubiquitin molecule and any one of the seven lysine 
residues  (as  well  as  the  N-terminal  methionine)  of  the  acceptor  ubiquitin.  Ubiquitin  conjugation 
through  different  chain  linkages  promotes  different  conformational  folds,  resulting  in  different 
structures  [6],  making  the  complexity  of  the  system  formidable.  Ubiquitin  can  modify  cysteines, 
serines and threonines as well as lysine residues. All these chains require removal or remodeling by 
de-ubiquitylating  enzymes  (DUBs),  producing  a  system  of  immense  complexity,  itself  requiring 
fine regulation.  
Viruses are by definition obligate intracellular parasites and have co-evolved in the face of strong 
host immune pressure. Given the importance of ubiquitin in the host cell, it is not surprising that 
viruses manipulate the ubiquitin pathway to further their own replication [7]. Indeed, exploiting the 
ubiquitin pathway provides the virus with an excellent mechanism for disposing of unwanted elements 
of the immune system. A good example of this activity comes from studies of the herpesviruses, large 
double-stranded DNA viruses that persist for the lifetime of the host, which have evolved multiple 
mechanisms to evade both innate and adaptive immune responses. The identification of K3 and K5 as 
viral  ubiquitin  E3  ligases  has  furthered  the  elucidation  of  how  Kaposi’s  Sarcoma  Associated 
Herpesvirus (KSHV) evades the host immune response, as well as providing an excellent system to 
study the role of ubiquitination in endocytosis.  
2. K3 and K5 Modulate Host Cell Surface Receptors 
At the turn of the century, several groups reported the downmodulation of cellular immunoreceptors 
by  novel  proteins  encoded  by  the  gamma  herpesviruses  [8–12].  Both  K3  and  K5  from  KSHV 
downregulate  cell  surface  MHC  I  molecules,  as  does  mK3,  the  homologue  from  murine 
gammaherpesvirus 68 (MHV-68). Radioimmune precipitation experiments showed that expression of 
mK3 led to the rapid degradation of endoglycosidase H sensitive MHC I, which could be rescued by 
proteasome inhibition [13]. In contrast, K3 and K5 did not interfere with MHC I synthesis, assembly 
or egress, but caused MHC I downregulation from the cell surface by enhancing endocytosis and 
lysosomal degradation [9–11].  
K3 and K5 show different HLA allotype specificities, as K3 downregulates HLA-A, -B, -C and Viruses 2011, 3                         
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HLA-E, while K5 effectively targets HLA-A and -B, HLA-C only weakly and is unable to target 
HLA-E [10]. While K3 appears to be focused on MHC I, K5 is much more promiscuous and is able to 
downregulate an increasing number of seemingly unrelated immunoreceptors, as described below.  
3. Bioinformatic Clues to K3 and K5’s Mechanism of Action  
Despite the KSHV and MHV-68 homologues K3, K5 and mK3 differing in their target specificity, 
as well as route of target degradation, clues as to their mechanism of action were gained from sequence 
analysis.  All  three  proteins  contain  an  N-terminal  motif  that  shares  similarities  with  both  plant 
homeodomain (PHD) or leukemia-associated protein (LAP) motifs and really interesting new gene 
(RING) domains [14]. The order of cysteine and histidine residues in these different sequences is 
subtly different, resulting in a different structural organization. PHD/LAP domains are implicated in 
transcriptional  regulation  and  protein-protein  interactions  and  have  a  conserved  C4HC3  sequence 
organization. RING domains have either a C3HC4 (RING-HC) or a C3H2C3 organization (RING-H2), 
and act as E3-ubiquitin ligases which direct substrates for ubiquitination. Since the RING domains of 
K3, K5 and mK3 do not strictly match either motif, we solved the NMR structure of the K3 RING to 
show  that  the  N-terminal  motif  common  to  the  gamma-herpesvirus  homologues,  despite  having  a 
C4HC3 motif, belonged to a new family of RING finger proteins termed RING-CH [15–17]. 
In addition to the N-terminal RING domain common to K3, K5 and mK3, these proteins also 
possess two long hydrophobic stretches predicted to encode transmembrane domains. Both N- and  
C-termini of mK3 are cytosolic, suggesting these new RING-CH containing proteins have a type III 
transmembrane  topology,  which  is  unusual  for  E3  ligases  [13].  Therefore,  bioinformatic  analysis 
predicted that K3, K5 and mK3 are viral E3-ubiquitin ligases, but could they direct the ubiquitination 
of substrates? 
4. The RING-CH Domains of mK3, K3 and K5 Direct Ubiquitination 
The use of proteasome or lysosomal inhibitors in cells expressing mK3, K3 or K5 allowed the 
visualization  of  ubiquitinated  MHC  I  species.  Ubiquitination  is  absolutely  dependent on an  intact 
RING domain. In cells treated with lactacystin, a characteristic ‘ubiquitin ladder’ was observed when 
MHC I was immunoprecipitated from cells expressing wild-type mK3 but not mK3 RING mutants. 
Re-immune  precipitation  with  an  anti-ubiquitin  antibody  identified  this  ladder  of  bands  as 
ubiquitinated MHC I [13]. Similarly, K3 ubiquitinates MHC I and mutation of a critical tryptophan in 
the K3 RING, which does not disrupt RING structure but prevents E2 binding, abolished MHC I 
ubiquitination [18]. In contrast, only K5 was able to ubiquitinate B7-2 [19]. 
5. mK3 is an ERAD E3 Ligase 
The endoplasmic reticulum (ER) associated degradation or ERAD pathway allows cells to dispose 
of proteins that fail their quality control checkpoints and are unable to progress through the secretory 
pathway. Misfolded proteins are selected by chaperones and retrotranslocated back across the ER 
membrane  to  the  cytosol  where  they  are  targeted  for  proteasome-mediated  degradation.  This 
retrotranslocation  step  requires  the  polyubiquitination  of  the  misfolded  substrate—the  critical  step Viruses 2011, 3                         
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involving mK3. By acting as a virally-encoded E3 ligase responsible for the polyubiquitination of 
MHC I, mK3 directs the class I to the cellular ERAD pathway with a requirement for the cellular 
proteins Derlin1 and p97 [20]. 
MK3 associates in the ER membrane with the TAP/tapasin/ MHC I peptide loading complex (PLC) 
where it is ideally located to ‘capture’ newly synthesized MHC I heavy chain [21]. In addition to direct 
ubiquitination of classical MHC I molecules, mK3 also targets TAP and tapasin resulting in impaired 
maturation of both classical MHC I and non-classical class I [22,23]. Indeed the stabilization of mK3 
by binding the PLC affords mK3 resistance to the effects of interferon-gamma (IFN). As IFN levels 
increase, levels of not only the PLC but also mK3 itself increase, allowing the viral protein to target 
the  newly  synthesized  MHC  I  for  ubiquitination  and  degradation.  While  the  majority  of  K5’s 
substrates  are  targeted  for  endocytosis  from  the  plasma  membrane  with  subsequent  lysosomal 
degradation, K5 has also been shown to target one of its substrates, PECAM/CD31, for degradation by 
the proteasome [24]. 
6. Endocytosis Induced by K3 and K5 
The constitutive ubiquitination directed by K3 and K5 to their target immunoreceptors provides a 
good model system for studying the cellular components necessary for endocytosis and degradation. 
Whereas  treatment  with  proteasome  inhibitors  prevents  the  degradation  of  ERAD  substrates, 
lysosomal inhibitors such as concanamycin A or bafilomycin A prevent the degradation of K3 and K5 
substrates targeted via the endolysosomal pathway. While K3 predominantly targets MHC I (as above) 
it is also reported to downregulate CD1d [25], PECAM [26] and IFN-R1 [27]. In contrast, K5 targets 
many immunoreceptors for downregulation. These include ligands for cytotoxic T cells (MHC I, as 
above)  and  the  related  HFE  protein  [28],  adhesion  molecules  (ICAM-1,  PECAM,  ALCAM,  and 
VE-cadherin) [29], costimulatory molecules (B7-2) [10], ligands for NKT cells (CD1d) [25], ligands 
for NK cells (MICA, MICB, AICL) [30], cytokine receptors (IFN-R1) [27], cellular restriction factors 
(BST-2 or tetherin) [31–33], the plasma membrane t-SNARE syntaxin-4 [31] and a member of the 
TGF-beta family (BMPRII) [34]. 
Mutational analysis of lysines in the cytosolic tail of HLA-A2 found that K3 preferentially targets 
the conserved membrane distal Lys340 [18], while K5 preferentially targets the conserved membrane 
proximal Lys335 [35,36]. Further analyses seem to confirm the general rule that K5 ubiquitinates 
lysines at or near the stop transfer sequence in the cytosolic tail of its substrates  [28,30,34]. This 
positively charged region found in the majority of type I membrane proteins prevents their ‘pullback’ 
into  the  hydrophobic  environment  of  the  phospholipid  membrane.  This  may  go  some  way  to 
explaining the increased substrate range of K5 versus K3, but cannot be the sole factor determining K5 
substrate recognition since many proteins with membrane proximal lysine residues are not targeted by 
K5. It is surprising that K5 can target this membrane-proximal lysine which in some cases is so close 
to the membrane that the positively charged residue might be predicted to be embedded within the 
phospholipid bilayer so as not to be available for ubiquitination. One idea is that the proximity of K5, 
itself a membrane protein, to its substrates may help expose the acceptor lysine for targeting. In their 
detailed analysis of ubiquitin acceptor sites, Cadwell and Coscoy [36] found that K5 not only prefers 
membrane  proximal  targets,  as  opposed  to  the  more  distal  targets  favored  by  K3,  but  that  the Viruses 2011, 3                         
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juxtamembrane cytoplasmic portions of K3 and K5 themselves contribute to this target preference. 
7. K3 and K5 Expose New Amino Acid Targets of Ubiquitination  
The discovery that K3 ubiquitinates MHC I lacking any cytosolic lysines led to a search for other 
ubiquitin acceptors [37]. The ubiquitination reaction was sensitive to reducing agents indicating the 
conjugation  was  cysteine-mediated  via  a  thioester  bond  [37].  Ubiquitination  of  an  additional  
HLA-B7  mutant  that  lacked  cytosolic  lysine  and  cysteine  residues  suggested  that  K3  could  also 
ubiquitinate other amino acid residues. K5 also ubiquitinates a membrane-proximal cysteine residue on 
MHC I [36], and mK3 can ubiquitinate substrates lacking cytosolic lysines through an oxyester linkage 
to the hydroxyl group on serines or threonines [38]. These findings spearheaded subsequent reports 
that non-lysine ubiquitination can also occur in non-viral cellular systems as reported for neurogenin 
degradation in Xenopus [39] and Hrd1-dependent ERAD of the T-cell antigen receptor -chain [40]. 
The frequency of these non-lysine ubiquitin acceptor sites remains to be determined. 
8. K3 and K5 Recruit Consecutive E2s to Polyubiquitinate MHC I Molecules via Lys63 Linkages 
for Endolysosomal Degradation 
While it was clear how polyubiquitination by mK3 would provide a signal for MHC I dislocation 
across  the  ER  membrane  for  proteasome-mediated  degradation,  more  puzzling  was  how  ubiquitin 
could  mediate  receptor  downregulation  from  the  cell  surface. The explanation  came  from a  yeast 
two-hybrid  experiment  to  identify  the  E2  which  binds  K3’s  RING  [15].  This  identified  UBE2N 
(Ubc13), a unique E2 conjugating enzyme which conjugates Lys63-linked, as opposed to the more 
canonical  Lys48-linked,  polyubiquitin  chains.  Rosine  Haguenauer-Tsapis’  group  had  previously 
shown in yeast that Lys63 linked polyubiquitin conjugates were required for internalization of yeast 
plasma membrane proteins [41] but a Lys63 linkage had not been reported for receptor internalization in 
higher eukaryotes. Indeed, in yeast as well as mammalian systems, some groups find that monoubiquitin 
provides a sufficient signal for receptor internalization [42,43]—an area which remains debated [44,45]. 
Using  a  panel  of  ubiquitin  mutants,  we  showed  that  Lys63  linked  polyubiquitin  chains  are  
required  for  internalization,  while  monoubiquitination  does  not  provide  a  sufficient  signal  [46]. 
Overexpression of an ubiquitin mutant lacking Lys63 (K63R) dramatically rescued MHC I surface 
expression in a K3-expressing cell, and biochemical analysis showed the ladder of polyubiquitinated 
class I species collapsed to a monoubiquitinated form. Further analyses with a lysine-less MHC I 
molecule fused to lysine-less ubiquitin revealed that internalization of this monoubiquitinated substrate 
was poor. Therefore Lys63 linked polyubiquitinated MHC I provides the signal for internalization via 
the  endocytic  pathway.  A  role  for  Lys63  is  now  seen  with  an  increasing  number  of  cell  surface 
receptors [47,48]. 
The  affinity  of  interactions  between  ubiquitin  and  ubiquitin-binding  (UBD)  domain-containing 
receptors along the endocytic pathway is low [49]. Therefore, multiple ubiquitins may increase the 
avidity and stabilize the interaction between ubiquitin and its corresponding UBD [42]. It would seem 
likely that this could occur through either multiple monoubiquitination or, for those receptors with a 
limited number of available cytoplasmic lysine residues, Lys63 polyubiquitin conjugates would offer 
an alternative option. Structural analysis shows Lys48 ubiquitin chains adopt a closed conformation, Viruses 2011, 3                         
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while Lys63 ubiquitin chains are in an extended conformation [50]. This extended topology is similar 
to adjacent linear ubiquitin chains which, unlike the Lys48 linkage, have their hydrophobic surfaces 
available for binding [51]. Thus, the open conformation of Lys63 polyubiquitin conjugates, as with the 
multiple monoubiquitins, may increase their avidity for UBDs.  
Another significant finding to emerge from the analysis of K3-mediated ubiquitin chain linkages 
was the identification and understanding of the cellular E2 enzymes recruited by K3. To our surprise, 
rather than resulting in a complete loss of polyubiquitinated MHC I, depletion of UBE2N (Ubc13) 
from K3-expressing cells induced a collapse of the polyubiquitinated MHC I to a monoubiquitinated 
MHC I species which was not efficiently internalized and remained at the cell surface [46]. In addition 
to reinforcing the finding that monoubiquitin provides an inefficient signal for MHC I internalization, 
this  result  implied  that  UBE2N  (Ubc13)  is  a  processive  enzyme  required  for  elongation  of  the 
monoubiquitinated MHC I species but was itself unable to initiate MHC I ubiquitination. Thus, the 
priming  of  MHC  I  with  a  single  ubiquitin  must  be  performed  by  an  additional  E2,  which  was 
subsequently  identified  as  UBE2N  (UbcH5).  This  requirement  for  two  E2  enzymes  in  a 
polyubiquitination reaction, where the first E2 primes the substrate, and the second E2 elongates the 
ubiquitin chain, is now well recognized in a number of ubiquitin systems. There is also a growing body 
of evidence that E3’s function in partnership with a limited number of E2s in vivo [4], and that this 
partnership may dictate the resulting polyubiquitin linkage [52].  
A stable substrate/E3/E2/ub complex composed of MHC I heavy chain, K3, UBE2N (Ubc13) and 
ubiquitin  was  visualized  by  overexpression  of  an  Ile44  mutant  (I44A)  of  ubiquitin  [53].  In  this 
instance, surface MHC I levels in K3 expressing cells are rescued because the K3 viral ligase is unable 
to discharge the ubiquitin mutant onto the MHC I substrate, resulting in a stabilization of the complex. 
In the presence of reducing agents, the thioester bond linking the ubiquitin mutant to UBE2N (Ubc13) 
is broken with resulting collapse of the complex. The use of similar ubiquitin mutants may enable the 
capture of transient substrate/E2/E3 complexes in the future. 
9. Internalization of MHC I by K5 Requires Mixed Lys11 and Lys63 Linked Polyubiquitin 
Chains on a Single Lysine Acceptor Residue 
In comparison with K3, the K5-mediated downregulation of MHC I is far less efficient though the 
reasons behind this still remain unclear. We analyzed the ubiquitin chain linkage generated by K5 to 
try and understand how K5 differs from K3 and whether this has an effect on the signals required for 
endocytosis. As we had previously seen with K3, UBE2D (UbcH5) was required to prime MHC I with 
a monoubiquitin, followed by recruitment of UBE2N (Ubc13), which elongates the ubiquitin chain. 
Mass  spectrometric  analysis  of  the  K5-generated  polyubiquitinated  MHC  I  species  showed  the 
presence of mixed polyubiquitin chains, involving Lys11- as well as Lys63-linkages, a finding which 
was confirmed in a series of functional experiments using ubiquitin mutants [35]. The critical point is 
that since these ubiquitination events occur on a single acceptor lysine residue in the tail of MHC I, 
this implies the presence of mixed Lys11- and Lys63-linked polyubiquitin chains. Mixed chains have 
been previously described in vitro [54], but our results are the first in vivo demonstration of mixed 
linkage polyubiquitin chains, a finding which was recently confirmed by Ishido’s group [55]. The 
order of chain linkages is not possible to predict, but the use of additional ubiquitin mutants suggest a Viruses 2011, 3                         
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forked chain topology was more likely than simple mixed chains [35]. We do not fully understand why 
mixed  chains  are  required  for  endocytosis.  The  proximity  of  the  acceptor  lysine  residue  to  the 
membrane phospholipid bilayer may impose constraints on the type of ubiquitin chain which can be 
formed. Alternatively, novel ubiquitin-binding domains may have specificity for either Lys11 or even 
mixed polyubiquitin chains. Although the requirements for these mixed chains are not understood, the 
demonstration of mixed ubiquitin chains reveals a further layer of complexity in the ubiquitin system 
and challenges the widely-held assumption that polyubiquitin chains are by necessity homogenous—
assumptions based mainly on in vitro data. 
10. Do Other Polyubiquitin Chains Substitute for Lys63 in MHC I Downregulation? 
The role of Lys63 linked polyubiquitin chains in MHC I downregulation by K5 was established 
using a mutant ubiquitin, in which Lys63 was mutated to arginine (K63R) and rescued MHC I back to 
the cell surface as determined by flow cytometry [35]. Further biochemical analysis of this ‘rescued’ 
MHC I high population showed that instead of the predicted monoubiquitinated MHC I band, the 
MHC I in these cells showed an increase in polyubiquitinated MHC I (Figure 1B, lane 5). This result 
suggests (i) K5 can induce non-Lys63 linked polyubiquitin chains, and (ii) these polyubiquitin chains 
do not provide a signal for endocytosis. Therefore, polyubiquitination is not enough—the chain has to 
be the correct linkage—presumably for recognition by the correct UBD-containing protein(s). 
Figure  1.  Polyubiquinated  MHC  I  lacking  Lys63  linkages  is  poorly  downregulated.  
(A)  Flow  cytometry  dot  plot  showing  HeLa  K5  cells  transduced  with  ubiquitin-GFP 
constructs as marked. (B) Radioimmune precipitation showing ubiquitinated class I heavy 
chains. Cells were pulse labeled for 10 minutes with 
35S-cysteine/methionine and chased 
for 60 minutes with unlabeled amino acids. Cells were then lysed in 1% Triton X-100 in 
tris- buffered saline in the presence of protease inhibitors. Cleared lysates were subjected 
to immunoprecipitation with w6/32, which recognizes conformational MHC I. Following 
denaturation at 70 °C in 1% SDS, class I heavy chain was reprecipitated with HC10 and 
electrophoresed on a 9% polyacrylamide gel prior to drying and exposure to film. 
 
11. Cellular Co-Factors Required for Endocytosis and Degradation of Polyubiquitinated Substrates 
The  K3-induced,  Lys63-linked  polyubiquitination  of  MHC  I  leads  to  rapid  internalization  and 
trafficking via multivesicular bodies (MVBs) for lysosomal degradation, and provides an ideal model Viruses 2011, 3                         
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system  to  identify  downstream  effectors  required  for  internalization  and  degradation.  Given  that 
substrates decorated with Lys63-linked polyubiquitin chains by K3 are efficiently endocytosed, an 
siRNA approach was used to identify additional proteins required for internalization. We found an 
absolute requirement for clathrin and the clathrin adaptor epsin 1 [46]. Components of the endosomal 
sorting complex required for transport or ESCRT pathway are also required. Specifically, depletion of 
the ESCRT I component Tsg101 leads to the recycling of MHC I back to the cell surface in K3 
positive cells because they can no longer be directed to MVBs [18], while depletion of ESCRT II 
components  had  no  effect  [56].  In  addition,  we  found  that  the  K3-mediated  internalization  of 
Lys63-polyubiquitinated class I molecules requires the epsin 1 and eps15R endocytic adaptors in a 
clathrin-dependent, but AP-2-independent pathway [46]. 
12. The K3 and K5 Viral E3 Ligases were Appropriated from the MARCH Family of Human E3 
Ligases 
RING-CH containing K3 homologues have been identified in poxviruses, where they were also 
found to downregulate cell surface receptors via ubiquitination [57], raising the question as to where 
this family of genes originated. Perhaps unsurprisingly they have been pirated from their vertebrate 
host. Indeed, identification of the Membrane Associated RING-CH family of E3 ligase (MARCH) 
proteins came from bioinformatic analyses based on the RING-CH and structural organization of K3, 
K5 and mK3 [16,17]. Eleven MARCH proteins can be identified in the human genome, exhibiting E3 
ligase functions in different tissues with diverse substrates. The identification of substrates for the  
MARCH proteins remains in its infancy. Indeed, only for MARCH 1 is a physiological substrate 
clearly defined, as MARCH 1 regulates MHC class II expression in B cells and immature dendritic 
cells (DCs) [58–60]. Indeed, MARCH 1-mediated ubiquitination of MHC II in immature DCs results 
in  degradation.  Under  these  circumstances,  ubiquitination  enhances  the  kinetics  of  degradation  of 
internalized MHC II-peptide complexes without affecting their rate of endocytosis from the plasma 
membrane [60]. For the remaining MARCH proteins, identification of substrates has proven more 
difficult as, unlike the viral ligases, protein expression is hard to detect, and no good antibodies are 
available. Several substrates have been identified based on overexpression of the respective MARCH 
protein and a search for targets identified either by (i) flow cytometry—by analogy to the known 
substrates of the K3 family [16,61], or (ii) a functional proteomic approach to examine the relative 
abundance  of  proteins  expressed  at  the  plasma  membrane  in  the  presence  or  absence  of  
MARCH 9 [62]. Table 1 shows a summary of what is known about these cellular E3 ligases in terms 
of their substrates, co-factors and ubiquitin linkage specificities. These include the early identification 
of MHC I as a potential target of both MARCH 4 and MARCH 9 [16], to their more recent target, the 
NKG2D ligand Mult1 [63]. ICAM-I, FCRIIB, SLAM, HLA-DQ, PTPRJ and ILT-2 are also potential 
targets of MARCH 9 identified by proteomics and confirmed by flow cytometry [62]. The proteomics 
approach  provides  a  useful  example  of  how  to  identify  ligase  substrates,  but  is  based  on  the 
assumption that the ligase degrades its substrate—which may not always be the case.  Viruses 2011, 3                         
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Table  1.  Summary  of  substrates,  ubiquitin  acceptors,  E2s,  ubiquitin  linkages  and  
de-ubiquitylating  enzymes  (DUBs)  for  herpesvirus  E3  ligases  and  their  cellular 
homologues. 
E3 ligases  substrates  1° Ub acceptor  E2s  linkage  DUBs 
K3  MHC I (HLA-A, HLA-B, HLA-C, 
HLA-E), CD1d, PECAM,  
IFN-R1 
Lys or Cys 10-15 
amino acids from 
the membrane 
UBE2D 
(UbcH5) and 
UBE2N 
(Ubc13) 
Lys63   
K5  MHC I (HLA-A, HLA-B, weakly 
HLA-C), HFE, CD1d, MIC-A, 
MIC-B, AICL, ICAM-1, PECAM, 
ALCAM, VE-cadherin, B7-2, 
IFN-R1, Syntaxin-4, BMPRII, 
BST-2/tetherin 
membrane 
proximal Lys or 
Cys 
UBE2D 
(UbcH5) and 
UBE2N 
(Ubc13) 
Lys63, 
Lys11 
 
mK3  MHC I, tapasin, TAP  Lys, Ser or Thr  Ube2J2 [64]  Lys48   
MARCH 1  MHC II  Lys       
MARCH 2  Transferrin receptor, B7-2, DLG1, 
binds syntaxin 6 [65] 
       
MARCH 3  binds syntaxin 6 [66]         
MARCH 4  MHC I, CD4, Mult1 (mice) [63]  Lys    Lys63   
MARCH 5  Drp1 [67]         
MARCH 6 
(TEB4) 
ERAD ligase [68]         
MARCH 7   unknown        USP7, 
USP9X [69] 
MARCH 8   MHC II, B7-2, Transferrin 
receptor 
Lys       
MARCH 9  MHC I, ICAM-1, CD4, FCRIIB, 
CD150, HLA-DQ, PTPRJ, ILT-2, 
Mult1 (mice) 
Lys       
MARCH 10  unknown         
MARCH 11  binds Veli-3 [70]         
 
13. Conclusions 
In  summary,  the  K3  family  of  viral  ubiquitin  E3  ligases  enable  viral  survival  and  replication 
through the downregulation of a large number of cell surface receptors including MHC I, a range of 
immunoreceptors as well as signaling receptors and cellular restriction factors. Equally importantly, 
the K3 family has provided powerful tools to dissect the role of ubiquitin in receptor regulation and 
endocytosis,  and  will  continue  to  shed  light  on  this  important  pathway,  for  instance  in  the 
identification of cellular deubiquitinases (DUBs) and adaptors. Characterization of the K3 viral family 
provided  the  impetus  for  identification  of  the  eleven  human  MARCH  family  members.  Current 
research is focused on the identification of substrates for these cellular E3 ligases and the physiological 
function of MARCH family members. Many important questions about MARCH function remain, Viruses 2011, 3                         
 
 
127 
including the identity of their E2 partners, the ubiquitin chain linkage, chain length and amino acid 
acceptor(s). In addition, the physiological consequence of ubiquitination, including the recruitment of 
adaptors and fate of the substrate require further characterization. 
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